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A B S T R A C T
The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) chikungunya (CHIKV), o’nyong-nyong (ONNV) and Mayaro virus (MAYV)
Working Group has been established to identify gaps of knowledge about the natural history, epidemiology and medical management of infection by these viruses,
and to provide adapted recommendations for future investigations. Here, we present a report dedicated to ONNV epidemiological distribution. Two large-scale ONNV
outbreaks have been identified in Africa in the last 60 years, interspersed with sporadic serosurveys and case reports of returning travelers. The assessment of the real
scale of ONNV circulation in Africa remains a difficult task and surveillance studies are necessary to fill this gap. The identification of ONNV etiology is made
complicated by the absence of multiplex tools in co-circulation areas and that of reference standards, as well as the high cross-reactivity with related pathogens
observed in serological tests, in particular with CHIKV. This is a specific obstacle for seroprevalence studies, that necessitate an improvement of serological tools to
provide robust results. The scarcity of existent genetic data currently limits molecular epidemiology studies. ONNV epidemiology would also benefit from reinforced
entomological and environmental surveillance. Finally, the natural history of the disease deserves to be further investigated, with a specific attention paid to long-
term complications. Considering our incomplete knowledge on ONNV distribution, GloPID-R CHIKV, ONNV and MAYV experts recommend that a major effort should
be done to fill existing gaps.
1. Introduction
O'nyong-nyong virus (ONNV) is a mosquito-borne alphavirus (fa-
mily Togaviridae), primarily transmitted through the bite of Anopheles
funestus and A. gambiae mosquitoes. After its first isolation from Gulu,
Uganda in 1959, ONNV was detected several times in humans and
mosquitoes (Rezza et al., 2017); so far, its known geographical dis-
tribution is confined to the African continent. It is highly probable that
ONNV has been misdiagnosed and/or underreported, because of the
circulation in Africa of pathogens causing similar illnesses (i.e., Plas-
modium falciparum, chikungunya virus (CHIKV), dengue virus (DENV),
and other arboviruses) and of the difficult interpretation of serological
results (due to cross-reactivity between antibodies against ONNV and
those against CHIKV) (Pezzi et al., 2019).
2. GloPID-R chikungunya (CHIKV), o'nyong-nyong (ONNV) and
Mayaro virus (MAYV) Working Group
The GloPID-R (Global Research Collaboration for Infectious Disease
Preparedness, https://www.glopid-r.org/) chikungunya (CHIKV),
o'nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group has
been established to investigate the natural history, epidemiology and
clinical aspects of these viruses; the objective was to identify knowledge
gaps and to propose recommendations for direct future investigations
and rectification measures. After the first report dedicated to diagnostic
aspects of CHIKV, ONNV and MAYV (Pezzi et al., 2019), here we pre-
sent an assessment of the available information regarding the epide-
miological distribution of ONNV. It will be followed by a report on
CHIKV and MAYV distribution.
3. Sources of data
Data from the first viral isolation until December 2018 were col-
lected, including both acute cases in humans (confirmed by PCR+ and/
or presence of IgM) as well as results of serological studies showing past
infections in humans (presence of IgG). Data were obtained from health
organizations and from the peer-reviewed literature concerning African
countries. We consulted different public health alert systems websites,
including:
• World Health Organization (WHO, 2019) - ‘Disease outbreak news
(DON)’ section• Program for Monitoring Emerging Diseases (ProMED);• European Centre for Disease Prevention and Control (ECDC)
through ‘Communicable disease threats report (CDTR)’;
• Institute of health of each African country, through periodic bulle-
tins on viral infections (when available).
In addition, a comprehensive review of literature using PubMED
was conducted with the search terms ‘O'nyong-nyong’ and the name of
each African country. Finally, viral sequences available in GenBank
were checked, in order to assess the countries where ONNV-positive
human samples have been collected.
In the article and in Tables 1–2 of Supplementary data we reported
details about ONNV detection: number of cases, year, localization and
technique(s) used to confirm the infection. We classified the sources of
our data in 5 categories:
• Declared outbreaks• Single case reports (mainly about returning travelers)• Surveillance studies, aiming to identify the etiology of acute ill-
nesses confirmed by PCR and/or serology• Serosurveys (to evaluate previous exposition to the virus, confirmed
by serological tools)• GenBank sequences, present on the database without additional
information on the isolated strains
In this report, experts provided a picture of ONNV geographic dis-
tribution through Africa over the last 60 years; in addition, they iden-
tified gaps of knowledge and made recommendations in order to sug-
gest research priorities in the field.
4. ONNV distribution
An account of the epidemiological findings about ONNV human
cases is shown below. Further details are presented in Table 1 (West
Africa) and Table 2 (Central and East Africa) of Supplementary data.
4.1. West Africa
4.1.1. Côte d’Ivoire
1) Outbreak
First reported epidemic caused by Igbo-Ora virus (later determined
to be a strain of ONNV). Cases were confirmed in Central Côte d'Ivoire
in 1984–1985 by serological tests or by virus isolation. Entomological
investigation allowed to detect the virus in A. funestus and A. gambiae
(Lhuillier et al., 1988).
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2) Outbreak
ONNV outbreak was declared in Nicla Border Camp in western Côte
d’Ivoire, among Liberian refugees (Posey et al., 2005). Cases were
confirmed positive by serological tests or PCR.
4.1.2. Ghana
1) Serosurvey
A seroprevalence study was performed in travelers returning from
tropical Africa in 1975–1977 (Woodruff et al., 1978). Sera from patients
with evidence of past infections were tested by haemagglutination in-
hibition (HI), complement fixation (CF), and indirect immuno-
fluorescence (IF) tests.
4.1.3. Nigeria
1) Case report
Two Igbo-Ora virus strains were isolated from two febrile children
in Oyo State, south-western Nigeria, in 1966 (Moore et al., 1975).
2) Case report
An Igbo-Ora virus strain was isolated from an adult patient living in
Oyo State, southwestern Nigeria, in 1969 (Moore et al., 1975).
3) Surveillance study
The seroprevalence study was performed in travellers returning
from tropical Africa (Woodruff et al., 1978) in 1975–1977. Sera from
patients with evidence of past infections were tested by haemaggluti-
nation inhibition (HI), complement fixation (CF), and indirect im-
munofluorescence (IF) tests. One ONNV infection dated back to June
1974, another one to December 1975. A third patient was infected in
Nigeria or in Sierra Leone, with no information about the year.
4) Serosurvey
Seroprevalence study performed among voluntary donors in Oyo
State, southwestern Nigeria (Olaleye et al., 1988). Sera were tested by
HI. Cross-reactivity with antibodies against CHIKV was observed.
4.1.4. Senegal
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Woodruff et al., 1978). A. funestus was
identified as the main vector (Lhuillier et al., 1988; Posey et al., 2005).
The first ONNV strain was isolated from Gulu (Uganda) in 1959.
4.2. Central and East Africa
4.2.1. Cameroon
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was iden-
tified as the main vector (Corbet et al., 1961; Williams et al., 1965). The
first ONNV strain was isolated from Gulu (Uganda) in 1959.
2) Serosurvey
A seroprevalence study performed in 2000–2003 involved adults in
nine rural villages in Cameroon. Sera were tested for ONNV by PRNT
(plaque-reduction neutralization test). Cross-reactivity with antibodies
against CHIKV was observed (Kuniholm et al., 2006).
3) Surveillance study
A study was conducted in 2004–2005 in the Fako Division (south-
west Cameroon). Sera were collected from febrile patients and tested by
haemagglutination inhibition (HI) and complement fixation (CF) tests,
with 34,2% and 33,3% of positive results, respectively. Cross-reactivity
with antibodies against CHIKV was observed (Fokam et al., 2010).
4.2.2. Central African Republic
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was iden-
tified as the main vector (Corbet et al., 1961; Williams et al., 1965). The
first ONNV strain was isolated from Gulu (Uganda) in 1959.
2) GenBank sequence (no additional information)
An Igbo-Ora strain of ONNV was isolated from human blood sample
in 1985. GenBank accession number available in Table 2- Supple-
mentary data.
4.2.3. Chad
1) Case report
Imported case - France ex Chad (southern part of the country)
(Bessaud et al., 2006). Sera was IgM+ and IgG + anti-ONNV by ELISA;
virus was isolated from peripheral blood mononuclear cells.
4.2.4. Democratic Republic of the Congo
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was iden-
tified as the main vector (Corbet et al., 1961; Williams et al., 1965). The
first ONNV strain was isolated from Gulu (Uganda) in 1959.
4.2.5. Kenya
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
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alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was iden-
tified as the main vector (Corbet et al., 1961; Williams et al., 1965). The
first ONNV strain was isolated from Gulu (Uganda) in 1959.
2) Serosurvey
Seroprevalence study was conducted in two sites in Western Kenya
in 1973: Kalo Plain (67,3% of positivity rate for ONNV) and Bunyala
(72,3%) (Marshall et al., 1982). Tests on sera were performed with HI.
3) Outbreak
A ONNV outbreak was first detected in south-central Uganda and
then spread to Kenya and Tanzania in 1996–1997 (Sanders et al.,
1999). A case-finding serosurvey conducted in January and February
1997 in affected sites in Uganda estimated infection rates at 45–68%.
Cross-reactivity with antibodies against CHIKV was observed.
4) Outbreak
ONNV cases were confirmed in Mombasa and Malindi districts
(eastern Kenya) in 2004 (ProMED, 20041216.3325).
5) Serosurvey
Seroprevalence study was performed on sera collected in Kwale
County, eastern Kenya, in 2009 [16]. Sera were tested with IgG ELISA
and PRNT (plaque reduction neutralization test). Cross-reactivity with
antibodies against CHIKV was observed, with 168 additional sera with
high titres for both viruses with PRNT.
Fig. 1. Acute ONNV cases in humans confirmed by PCR or virus isolation. Countries (in green) where ONNV infections have been confirmed by HI, VNT, PRNT, IF or
ELISA are not classified in the map since massive cross-reactivity with related alphaviruses affects serological assays.
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6) Case report
Imported case - Germany ex Kenya in 2013 (Tappe et al., 2014).
After a travel in eastern Africa, paired sera were tested by immuno-
fluorescence (IF) and virus neutralization (VNT) tests.
4.2.6. Malawi
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was iden-
tified as the main vector (Corbet et al., 1961; Williams et al., 1965). The
first ONNV strain was isolated from Gulu (Uganda) in 1959.
4.2.7. Mozambique
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was iden-
tified as the main vector (Corbet et al., 1961; Williams et al., 1965). The
first ONNV strain was isolated from Gulu (Uganda) in 1959.
4.2.8. South Sudan
1) Outbreak
During an outbreak of haemorrhagic fever syndrome in 2015–2016,
5 sera collected from patients and tested with PCR, PRNT and ELISA
were ONNV+ (O | Haemorrhagic fever, 2016).
4.2.9. Tanzania
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Woodruff et al., 1978). A. funestus was
identified as the main vector (Lhuillier et al., 1988; Posey et al., 2005).
The first ONNV strain was isolated from Gulu (Uganda) in 1959.
2) Outbreak
A ONNV outbreak was first detected in south-central Uganda and
then spread to Kenya and Tanzania in 1996–1997 (Sanders et al.,
1999). A case-finding serosurvey conducted in January and February
1997 in affected sites in Uganda estimated infection rates at 45–68%.
Cross-reactivity with antibodies against CHIKV was observed.
4.2.10. Uganda
1) Outbreak
A ONNV outbreak involving both eastern and western Africa
(Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon,
Central African Republic, Democratic Republic of the Congo) in
1959–1962 accounted for more than 2 million cases in eastern Africa
alone (Rezza et al., 2017; Woodruff et al., 1978). A. funestus was
identified as the main vector (Lhuillier et al., 1988; Posey et al., 2005).
The first ONNV strain was isolated from Gulu (Uganda) in 1959.
2) Outbreak
A ONNV outbreak was first detected in south-central Uganda and
then spread to Kenya and Tanzania in 1996–1997 (Sanders et al.,
1999). A case-finding serosurvey conducted in January and February
1997 in affected sites in Uganda estimated infection rates at 45–68%.
Cross-reactivity with antibodies against CHIKV was observed. ONNV
distribution is presented in Fig. 1.
Fig. 2. Phylogenetic analysis of 9 ONNV strains (including Igbo Ora, considered an ONNV strain) present in GenBank. Neighbor-joining phylogeny tree was gen-
erated using p-distance model with 1000 bootstrap replication. 1044 sites were included from partial E2-E1 sequences. Tip labels indicate GenBank accession
number, strain name, country and year of isolation. For NC_001512, sampling country and year are not available.
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5. Discussion
In this paper, we report cases of ONNV infections in humans;
however, the assessment of ONNV circulation in Africa remains a dif-
ficult task for several reasons.
First, the absence of surveillance in most African countries led to
fragmentary data including mainly isolated case reports of local people
or returning travelers, and sporadic outbreaks. Returning travelers can
serve as sentinels, providing information on recent circulation of an
infectious pathogen, especially in countries where laboratory diagnosis,
especially seroneutralization, is difficult to implement. However, the
diagnosis of imported ONNV infections should not only constitute a
detection for its own sake, but also provide evidence of viral circulation
and transmission in source countries that often do not have the diag-
nostic capacity to rule in ONNV. Similarly, outbreaks have been re-
ported but not followed by systematic seroprevalence, cross-sectional or
follow-up studies; their implementation is necessary in order to eval-
uate the real scale of ONNV circulation and to identify possible sequelae
post-infection. This is valid especially for countries that have already
experienced large-scale outbreaks (i.e. Kenya, Uganda, Tanzania), and/
or where ONNV circulation is suspected to be endemic (LaBeaud et al.,
2015).
Second, the scarce seroprevalence data currently available are not
robust, due to the cross-reactivity with antibodies raised against closely
related alphaviruses. In particular, in several serosurveys described in
the article it was hard to discriminate infections caused by ONNV and
those caused by CHIKV, since antibodies against the two viruses
strongly cross-react if tested by immunofluorescence test (IF), enzyme-
linked immunosorbent assay (ELISA), complement fixation test (CF) or
haemagglutination inhibition Test (HI) (Woodruff et al., 1978; Olaleye
et al., 1988; Fokam et al., 2010). Even neutralization tests, normally the
gold standard for specificity, are cross-reactive, sometimes in an
asymmetric manner (Pezzi et al., 2019). For example, LaBeaud et al.
observed that 38% of ONNV- and CHIKV-positive samples had high
titers for both alphaviruses using PRNT, and were then classified as
“equivocal” (LaBeaud et al., 2015). The presence of antibodies against
ONNV and CHIKV may sometimes be the result of infection by both
viruses (which would imply that infection by one pathogen does not
provide protection against the other), or may be due to massive cross-
reactivity because of the antigenic similarity between the two viruses.
However, strong cross-protection has been reported in studies of CHIKV
vaccines, suggesting that most cross-reactivity results from single in-
fections (Partidos et al., 2012). Since ONNV and CHIKV are phylo-
genetically close, some degree of cross-protection is highly probable;
dual reactivity against both ONNV and CHIKV is likely to reflect the
limited discriminatory capacity of available neutralization assays. An-
other explanation could be the circulation of a novel third virus that
induces antibodies that cross-neutralize both CHIKV and ONNV.
Third, the scarcity of available ONNV genetic data limits molecular
epidemiology studies and makes difficult to map viral spread
throughout Africa. According to the 9th report of the International
Committee on Taxonomy of Viruses (ICTV) (Genus, 2019), ONNV forms
with CHIKV a monophyletic group within the Semliki Forest complex.
Phylogenetic analysis with partial genome sequences available from
GenBank shows that ONNV isolates constitute a distinct evolutionary
branch apart from all CHIKV strains, with two major clades among
ONNV strains (Fig. 2) (Powers et al., 2000). The relationship among
viral strains does not depend on sample year and/or location, sug-
gesting frequent movement of ONNV through the African continent.
Igbo Ora virus, first isolated in 1966 from Nigerian patients and
sometimes considered as a separate virus, is closely related to an ONNV
strain isolated during 1996–97 outbreak in Uganda, supporting the idea
that it should be considered a member of species ONNV (Genus, 2019;
Lanciotti et al., 1998).
The analysis of the distribution of ONNV cases in time and space
suggests a certain periodicity of outbreaks and geographical limitations
in viral spread. ONNV has been capable of causing two known large-
scale epidemics, one in 1959–1962 and the following one in
1996–1997. As concerns geographical distribution of ONNV cases,
Fig. 1 shows a restriction to sub-Saharan countries in both East and
West Africa. Since ONNV is transmitted by malaria vector mosquitoes
(Anopheles species), it is not surprising that our ONNV map and those
reporting Anopheles and malaria cases distribution are overlapping
(Annual Report | About |P, 2019; Guerra et al., 2008). The relationship
between ONNV and malaria transmission remains to be investigated.
An unusual drop in malaria transmission was noted at the same time as
intense circulation of ONNV in southern Uganda during the 1959–1962
epidemic, in a period of the year with favorable meteorological con-
ditions for high mosquito densities (de Zulueta et al., 1962). This ob-
servation raises interesting questions regarding the growth and trans-
mission of malaria parasites (Plasmodium falciparum) in the anopheles
mosquitoes infected by ONNV.
Investigating the relationship between ONNV and co-circulating
pathogens (primarily CHIKV), as well as factors that limit ONNV dis-
tribution at regular intervals to some sub-Saharan countries other than
the diffusion of competent vectors (i.e. the presence of natural re-
servoirs) would most probably improve our understanding of ONNV
epidemiology.
According to available data on ONNV distribution, experts identi-
fied several gaps of knowledge and provided adapted recommendations
(Paragraphs 6and 7. The aim was to identify and suggest research
priorities in the field.
6. Gaps of knowledge
6.1. Disease surveillance and epidemiology
Despite ONNV detection in humans, vertebrates and mosquitoes
throughout African continent, the surveillance strategy remains un-
satisfactory. In some African countries, evidence for ONNV circulation
relies on small identified outbreaks (South Sudan, Côte d’Ivoire) or
single case reports (Chad, Ghana); in others, few seroprevalence studies
have been performed (Nigeria, Kenya) but the robustness of data is
disputable. Altogether, the scarcity of currently available information
does not allow to provide a clear picture of the actual scale of virus
spread.
6.2. Entomological and environmental surveillance
Despite the epidemiologic studies described above, fundamental
information on ONNV maintenance, presumably through an enzootic
cycle, remains wanting. This information includes both enzootic re-
servoir or amplification hosts, enzootic vectors, and mechanisms of
human-mosquito-human epidemic emergence.
6.3. Laboratory tests for seroprevalence studies
The close phylogenetic relationship between ONNV and CHIKV
explains why anti-ONNV and anti-CHIKV antibodies can barely be
distinguished. This is very difficult –if not impossible-using standard
ELISA or immunofluorescence test (Pezzi et al., 2019), but even ser-
oneutralization tests often generate equivocal results. Accordingly, the
choice of the best laboratory test to use in seroprevalence studies is
crucial, but it is doubtful that adapted and convenient serological tools
and interpretation algorithms are currently available to expedite ac-
curate (and large scale) seroepidemiological studies.
6.4. Diagnosis of acute cases
Very few incident cases are reported, most probably because diag-
nostic tests that should be used at the acute phase of the disease are
rarely available. IgM serological assays have not been evaluated, most
L. Pezzi, et al. Antiviral Research 172 (2019) 104611
6
probably poorly discriminate with CHIKV, and commercial kits do not
exist. Very few molecular assays for ONNV detection exist, and their
performances (in terms of specificity and sensitivity) have never been
evaluated through comparative studies. In practice they are rarely
available and used (Pezzi et al., 2019). Information about kinetics of viral
load are scarce and concern just sera samples; other body fluids have
never been tested. No International Standards (IS) are currently available
and External Quality Assessment (EQAs) have never been organized to
evaluate laboratories capacity to diagnose ONNV infection.
6.5. Cross-protection
It is unknown whether individuals infected by ONNV or CHIKV can
secondarily be infected by the other virus. It is presumed, due to the
close antigenic relationship, that the infection by one virus protects
against subsequent infection by the other, but since the seroneutralizing
relationship is not symmetric (antibodies to CHIKV provide better
protection against ONNV than the opposite), this remains to be con-
firmed. In addition, serological patterns associated with sequential ex-
posure to the two viruses are not characterized.
6.6. Natural history
The natural history of the disease deserves to be better investigated,
including acute manifestations and long-term sequelae. Moreover,
whereas a variety of long-term (mostly rheumatologic) complications of
the disease have been observed for the related chikungunya virus since
the Indian Ocean outbreak (constituting an actual “post-CHIK” syn-
drome), longitudinal studies of ONNV infections have not been per-
formed to determine whether a “post-ONN” syndrome exists.
7. Expert recommendations
7.1. Disease surveillance and epidemiology
Specific efforts are required for improving our knowledge about
ONNV circulation and epidemiology at a large scale (including clinical
epidemiology). ONNV should be more frequently included in molecular
diagnostic panels for febrile illnesses of unknown origin in Africa, and
seroprevalence studies should be performed. This obviously requires
improved diagnostic assays and access.
7.2. Entomological and environmental surveillance
Entomology studies (including investigation of possible vector
switches) and characterization of the natural enzootic cycle in re-
servoirs and vectors should be promoted.
7.3. Laboratory tests for seroprevalence studies
Accurate assays and algorithms allowing to detect IgG antibodies to
ONNV and to distinguish them from IgG to CHIKV are needed. At this
stage, performing seroneutralization confirmation is mandatory after
performing a screening assay (e.g. ELISA, HI or IF assays) and allows
asserting ONNV circulation when titers against ONNV are clearly
higher than those against CHIKV. However, a proportion of samples
remains without clear identification, in particular in case of co-circu-
lation of both viruses (LaBeaud et al., 2015). Clear interpretation
guidelines or new specific assays are required and reference serological
standards are needed (possibly produced from non-human primates
(Pezzi et al., 2019),).
7.4. Diagnosis of acute cases
For diagnosis at the acute stage of the disease, viral co-circulation
requires the development of molecular and serological multiplex tools
to differentiate ONNV from CHIKV in Africa. Identification and analysis
of acute cases is mandatory to better know the natural history of the
disease and identify severe and complicated forms. Viremia kinetics and
viral loads in different body fluids should be better documented, as well
as the kinetics of immune response. International Standards (IS) should
be made available, both molecular and serological. Moreover, External
Quality Assessments (EQAs) should be organized in order to assess la-
boratory capacity of detecting ONNV with both molecular and ser-
ological tools.
7.5. Cross-protection
Cross-protection studies between ONNV and related alphaviruses, in
particular CHIKV, should be implemented. This could be done using
samples from both naturally exposed humans and experimentally in-
fected non-human primates.
7.6. Natural history
Studies should be performed in order to better characterize the
natural history of ONN disease and to identify long term sequelae post
infection.
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